{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:27:55Z","timestamp":1793392075402,"version":"4.5.0"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malignant pleural diseases involves both primary pleural malignancies (e.g., mesothelioma) as well as metastatic disease involving the pleura. The management of primary pleural malignancies remains a challenge, given their limited response to conventional treatments such as surgery, systemic chemotherapy, and immunotherapy. In this article, we aimed to review the management of primary pleural malignancy as well as malignant pleural effusion and assess the current state of intrapleural anticancer therapies. We review the role intrapleural chemotherapy, immunotherapy, and immunogene therapy, as well as oncolytic viral, therapy and intrapleural drug device combination. We further discuss that while the pleural space offers a unique opportunity for local therapy as an adjuvant option to systemic therapy and may help decrease some of the systemic side effects, further patient outcome-oriented research is needed to determine the exact role of these treatments within the armamentarium of currently available options.<\/jats:p>","DOI":"10.1055\/s-0043-1769094","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T23:20:08Z","timestamp":1686612008000},"page":"462-467","source":"Crossref","is-referenced-by-count":5,"title":["Intrapleural Anticancer Therapy for Malignant Pleural Diseases: Facts or Fiction?"],"prefix":"10.1055","volume":"44","author":[{"given":"Abhinav","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Zucker School of Medicine at Hofstra\/Northwell, New Hyde Park, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Chaddha","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Shojaee","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","article-title":"Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score","volume":"69","author":"A O Clive","year":"2014","journal-title":"Thorax"},{"issue":"14","key":"ref2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"N J Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"G Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"P Baas","year":"2021","journal-title":"Lancet"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients","volume":"117","author":"D J Sugarbaker","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.chest.2021.03.059","article-title":"Breast and lung effusion survival score models: improving survival prediction in patients with malignant pleural effusion and metastasis","volume":"160","author":"S Molina","year":"2021","journal-title":"Chest"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. an official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"D J Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.chest.2017.08.026","article-title":"Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions","volume":"153","author":"D E Ost","year":"2018","journal-title":"Chest"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000491934","article-title":"The hospital and patient burden of indwelling pleural catheters: a retrospective case series of 210 indwelling pleural catheter insertions","volume":"97","author":"R Asciak","year":"2019","journal-title":"Respiration"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21037\/jtd.2017.04.65","article-title":"Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS","volume":"9","author":"R Hu","year":"2017","journal-title":"J Thorac Dis"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.21037\/atm-20-6514","article-title":"A narrative review of hyperthermic intrathoracic chemotherapy for advanced lung cancer","volume":"9","author":"K Song","year":"2021","journal-title":"Ann Transl Med"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12885-016-2935-4","article-title":"Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis","volume":"16","author":"R Biaoxue","year":"2016","journal-title":"BMC Cancer"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/02656736.2017.1301576","article-title":"Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI)","volume":"33","author":"D Go\u00e9r\u00e9","year":"2017","journal-title":"Int J Hyperthermia"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtcvs.2017.10.070","article-title":"Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: a 10-year experience","volume":"155","author":"M C Ambrogi","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"E H Baldini","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"955","DOI":"10.21037\/atm-20-5444","article-title":"Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies","volume":"9","author":"T Markowiak","year":"2021","journal-title":"Ann Transl Med"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"960","DOI":"10.21037\/atm-20-7247","article-title":"Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma","volume":"9","author":"M Migliore","year":"2021","journal-title":"Ann Transl Med"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1569-9293(03)00197-X","article-title":"Combined surgery of intrapleural perfusion hyperthermic chemotherapy and panpleuropneumonectomy for lung cancer with advanced pleural spread: a pilot study","volume":"2","author":"N Shigemura","year":"2003","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1510\/icvts.2009.225110","article-title":"Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination","volume":"10","author":"M Kimura","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"153","key":"ref20","doi-asserted-by":"crossref","first-page":"190018","DOI":"10.1183\/16000617.0018-2019","article-title":"Does cytoreduction surgery and hyperthermic intrathoracic chemotherapy prolong survival in patients with N0-N1 nonsmall cell lung cancer and malignant pleural effusion?","volume":"28","author":"M Migliore","year":"2019","journal-title":"Eur Respir Rev"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.21037\/jtd.2019.05.25","article-title":"Clinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial","volume":"11","author":"A Kleontas","year":"2019","journal-title":"J Thorac Dis"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1183\/09031936.05.00037004","article-title":"Vascular endothelial growth factor in pleural effusions of different origin","volume":"25","author":"U Sack","year":"2005","journal-title":"Eur Respir J"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"L119","DOI":"10.1152\/ajplung.2001.281.1.L119","article-title":"Bacterial induction of pleural mesothelial monolayer barrier dysfunction","volume":"281","author":"K A Mohammed","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"52","key":"ref24","doi-asserted-by":"crossref","first-page":"e32207","DOI":"10.1097\/MD.0000000000032207","article-title":"Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: a meta-analysis","volume":"101","author":"Y Hu","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"40","key":"ref25","doi-asserted-by":"crossref","first-page":"e30749","DOI":"10.1097\/MD.0000000000030749","article-title":"Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: a meta-analysis and systematic review","volume":"101","author":"C Q Wang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"s4613","DOI":"10.1158\/1078-0432.CCR-07-0647","article-title":"Bevacizumab in non small cell lung cancer","volume":"13","author":"A Sandler","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"06","key":"ref27","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3892\/or.2013.2349","article-title":"Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion","volume":"29","author":"N Du","year":"2013","journal-title":"Oncol Rep"},{"issue":"47","key":"ref28","doi-asserted-by":"crossref","first-page":"e5392","DOI":"10.1097\/MD.0000000000005392","article-title":"Combination use of paclitaxel and Avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion","volume":"95","author":"N Qi","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/fon-2021-1035","article-title":"A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion","volume":"18","author":"W Di","year":"2022","journal-title":"Future Oncol"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/1759-7714.14361","article-title":"Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: a systematic literature review and pooled analysis","volume":"13","author":"I Karampinis","year":"2022","journal-title":"Thorac Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"961440","DOI":"10.3389\/fonc.2022.961440","article-title":"Current status of and progress in the treatment of malignant pleural effusion of lung cancer","volume":"12","author":"Y Zhao","year":"2023","journal-title":"Front Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"760683","DOI":"10.3389\/fimmu.2021.760683","article-title":"Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion","volume":"12","author":"X Li","year":"2021","journal-title":"Front Immunol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.12845","article-title":"Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer","volume":"186","author":"C Y Hu","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","article-title":"Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study","volume":"72","author":"S H Goey","year":"1995","journal-title":"Br J Cancer"},{"issue":"08","key":"ref35","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8","article-title":"Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma","volume":"67","author":"C Boutin","year":"1991","journal-title":"Cancer"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N","article-title":"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma","volume":"74","author":"C Boutin","year":"1994","journal-title":"Cancer"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1378\/chest.121.6.1921","article-title":"Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study","volume":"121","author":"I Monnet","year":"2002","journal-title":"Chest"},{"issue":"02","key":"ref38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"G L Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"A R Haas","year":"2019","journal-title":"Mol Ther"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"P S Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"issue":"01","key":"ref41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijc.2910320107","article-title":"Lysis of fresh human tumor cells by autologous large granular lymphocytes from peripheral blood and pleural effusions","volume":"32","author":"A Uchida","year":"1983","journal-title":"Int J Cancer"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00205392","article-title":"Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes","volume":"18","author":"A Uchida","year":"1984","journal-title":"Cancer Immunol Immunother"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1440-1843.2006.00790.x","article-title":"Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer","volume":"11","author":"A Ishida","year":"2006","journal-title":"Respirology"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.lungcan.2007.07.009","article-title":"Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515","volume":"58","author":"K Yoshida","year":"2007","journal-title":"Lung Cancer"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","article-title":"A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses","volume":"13","author":"D H Sterman","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/mt.2009.309","article-title":"A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions","volume":"18","author":"D H Sterman","year":"2010","journal-title":"Mol Ther"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"D H Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"15","key":"ref48","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"D H Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00262-015-1679-3","article-title":"Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma","volume":"64","author":"L K Aguilar","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ymthe.2018.02.015","article-title":"Phase I study of intrapleural gene-mediated cytotoxic immunotherapy in patients with malignant pleural effusion","volume":"26","author":"C Aggarwal","year":"2018","journal-title":"Mol Ther"},{"issue":"25","key":"ref51","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"R H Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma - A phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"S J Danson","year":"2020","journal-title":"Lung Cancer"},{"issue":"05","key":"ref53","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.athoracsur.2012.02.009","article-title":"Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma","volume":"93","author":"J S Friedberg","year":"2012","journal-title":"Ann Thorac Surg"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.seminoncol.2014.09.017","article-title":"Photodynamic therapy for lung cancer and malignant pleural mesothelioma","volume":"41","author":"C B Simone II","year":"2014","journal-title":"Semin Oncol"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/BF02303746","article-title":"Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma","volume":"4","author":"H I Pass","year":"1997","journal-title":"Ann Surg Oncol"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.athoracsur.2014.12.077","article-title":"Intrapleural photodynamic therapy for mesothelioma: what place and which future?","volume":"99","author":"C Munck","year":"2015","journal-title":"Ann Thorac Surg"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1769094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T23:54:08Z","timestamp":1689033248000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1769094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":56,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,7,10]]},"published-print":{"date-parts":[[2023,8]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1769094","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]}}}